LEXINGTON, Mass., Sept. 5, 2018 /PRNewswire/ -- AgenTus
Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated
to advancing breakthrough "living drugs" for potentially curative
treatments for patients with cancer, announced today that Dr.
Cherylene Plewa, Senior Director,
Molecular Biology, AgenTus Therapeutics will present at the CAR-TCR
Summit in Boston on September 6, 2018.
Dr. Plewa will present two posters on the
T-Rx™ Platform technology, a proprietary
state-of-the-art drug discovery engine that enables rapid discovery
of T cell receptors (TCRs). Dr. Plewa will also share
preclinical data on the ability of two T-Rx-discovered TCRs to
recognize and kill tumor cells: a fully-human
phosphopeptide-specific TCR and another that targets NY-ESO-1, an
antigen that is widely expressed in multiple cancer
indications.
Poster Presentation Details:
Poster 1: A mammalian display-based platform for T Cell Receptor
(TCR) discovery and identification of novel TCRs targeting
NY-ESO-1
Poster 2: Discovery of phospho-peptide neoantigen tumor targets
(PTTs) and identification of novel T cell receptors (TCRs)
targeting phospho-MLL for adoptive cell therapy
Date: Thursday, September 6,
2018
Time & Location: 8:00am at
Commonwealth Hall Salon C, Seaport WTC Hotel, Boston, MA
About AgenTus Therapeutics, Inc.
AgenTus
Therapeutics is a preclinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
breakthrough "living drugs" to advance potential cures for cancer
patients. AgenTus employs naturally-derived and engineered
receptors, specifically T cell receptors (TCRs) and Chimeric
Antigen Receptors (CARs), designed to supercharge human immune
effector cells to seek and destroy cancer. AgenTus also aims
to advance adoptive cell therapy formats which would enable
off-the-shelf living drugs. AgenTus has locations in
Lexington, MA and Cambridge, UK. For more information,
please visit www.agentustherapeutics.com.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, proprietary
cancer vaccine platforms, and adoptive cell therapies (through its
AgenTus Therapeutics subsidiary). The Company is equipped with a
suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding AgenTus' planned
presentation at the CAR-TCR Summit in Boston, MA and the company's research and
development plans and activities. These forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of Agenus' most recent Quarterly Report on Form 10-Q or
Annual Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/agentus-therapeutics-to-present-on-the-anti-tumor-activities-of-two-proprietary-t-cell-receptors-tcrs-at-car-tcr-summit-in-boston-ma-300707644.html
SOURCE AgenTus Therapeutics, Inc.